Axsome Therapeutics Inc (AXSM) Given Consensus Rating of “Buy” by Brokerages

Shares of Axsome Therapeutics Inc (NASDAQ:AXSM) have been assigned a consensus recommendation of “Buy” from the nine analysts that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $28.00.

A number of research firms have recently commented on AXSM. Zacks Investment Research upgraded Axsome Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, April 3rd. BidaskClub upgraded Axsome Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, March 26th. ValuEngine downgraded Axsome Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, December 21st. HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective on shares of Axsome Therapeutics in a report on Thursday, January 31st. Finally, Cantor Fitzgerald raised their price target on Axsome Therapeutics from $16.00 to $25.00 and gave the stock an “overweight” rating in a research note on Thursday, March 21st.

In other news, CFO Nick Pizzie purchased 5,400 shares of the company’s stock in a transaction that occurred on Tuesday, March 19th. The shares were purchased at an average price of $12.58 per share, for a total transaction of $67,932.00. Following the purchase, the chief financial officer now directly owns 36,340 shares of the company’s stock, valued at approximately $457,157.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Mark Coleman purchased 5,100 shares of the company’s stock in a transaction that occurred on Tuesday, March 19th. The shares were purchased at an average price of $12.18 per share, for a total transaction of $62,118.00. The disclosure for this purchase can be found here. Company insiders own 34.30% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in AXSM. Barclays PLC acquired a new stake in Axsome Therapeutics during the 4th quarter worth approximately $30,000. Bank of New York Mellon Corp acquired a new stake in Axsome Therapeutics during the 4th quarter worth approximately $98,000. Worth Venture Partners LLC acquired a new stake in Axsome Therapeutics during the 3rd quarter worth approximately $138,000. BlackRock Inc. lifted its position in Axsome Therapeutics by 14.6% during the 4th quarter. BlackRock Inc. now owns 64,049 shares of the company’s stock worth $181,000 after acquiring an additional 8,137 shares during the period. Finally, Tibra Equities Europe Ltd acquired a new stake in Axsome Therapeutics during the 1st quarter worth approximately $319,000. Hedge funds and other institutional investors own 11.57% of the company’s stock.

Shares of AXSM traded down $0.58 during mid-day trading on Wednesday, reaching $14.90. The company’s stock had a trading volume of 1,217,873 shares, compared to its average volume of 2,295,673. Axsome Therapeutics has a 12-month low of $1.94 and a 12-month high of $16.80. The company has a market cap of $515.17 million, a P/E ratio of -12.96 and a beta of 3.48. The company has a debt-to-equity ratio of 3.86, a quick ratio of 1.41 and a current ratio of 1.41.

Axsome Therapeutics (NASDAQ:AXSM) last released its quarterly earnings data on Thursday, March 14th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.01. As a group, analysts predict that Axsome Therapeutics will post -1.13 earnings per share for the current fiscal year.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a clinical stage biopharmaceutical company, is developing novel therapies for central nervous system (CNS) disorders. Its product candidate portfolio includes AXS-05, AXS-09, AXS-02, AXS-07, and AXS-06. AXS-05 is in the Phase III clinical trial in treatment resistant depression and in agitation associated with Alzheimer's disease, as well as in the Phase II clinical trial for smoking cessation.

Recommended Story: Analyst Ratings Trading

Analyst Recommendations for Axsome Therapeutics (NASDAQ:AXSM)

Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.